0000000000349940
AUTHOR
Katharina Lechner
The McCAVE Trial: Vanucizumab plus mFOLFOX‐6 Versus Bevacizumab plus mFOLFOX‐6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC)
Abstract Background Bevacizumab, a VEGF‐A inhibitor, in combination with chemotherapy, has proven to increase progression‐free survival (PFS) and overall survival in multiple lines of therapy of metastatic colorectal cancer (mCRC). The angiogenic factor angiopoetin‐2 (Ang‐2) is associated with poor prognosis in many cancers, including mCRC. Preclinical models demonstrate improved activity when inhibiting both VEGF‐A and Ang‐2, suggesting that the dual VEGF‐A and Ang‐2 blocker vanucizumab (RO5520985 or RG‐7221) may improve clinical outcomes. This phase II trial evaluated the efficacy of vanucizumab plus modified (m)FOLFOX‐6 (folinic acid (leucovorin), fluorouracil (5‐FU) and oxaliplatin) ver…
Degassing regime of Hekla volcano 2012-2013
Hekla is a frequently active volcano with an infamously short pre-eruptive warning period. Our project contributes to the ongoing work on improving Hekla's monitoring and early warning systems. In 2012 we began monitoring gas release at Hekla. The dataset comprises semi-permanent near-real time measurements with a MultiGAS system, quantification of diffuse gas flux, and direct samples analysed for composition and isotopes (δ13C, δD and δ18O). In addition, we used reaction path modelling to derive information on the origin and reaction pathways of the gas emissions.Hekla's quiescent gas composition was CO2-dominated (0.8mol fraction) and the δ13C signature was consistent with published value…